app_store_button

google_play_button

Device Banner Block-copy 894x1036

Astu lugude lõputusse maailma

Loe ja kuula

Bloomberg

Barry Ritholtz speaks with the people that shape markets, investing and business.

Masters in Business

Rachel Benton is a loving mother to an adorable 2-year-old boy named Stetson. Stetson doesn’t know it, but he may have already saved his mom’s life. A routine medical checkup, that Rachel only had because she was pregnant, showed protein in her urine. That discovery led to a biopsy and ultimately a diagnosis of IgA nephropathy – a serious kidney disease. With patients like Rachel in mind, the research team at Vertex Pharmaceuticals is working on new approaches to address IgA nephropathy. 
 
Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.

See omnystudio.com/listener for privacy information.

Targeting IgA Nephropathy (Sponsored Content)

Barry speaks with Brandon Zick, Chief Investment Officer at Ceres Partners. They discuss how his private equity company invests in farmland, and food, agriculture and water. They also discussed his path into finance from growing up on a farm, to studying finance and Japanese in college.

See omnystudio.com/listener for privacy information.

Ceres Partners CIO Brandon Zick on How Private Equity Invests in Farmland

Have you taken full advantage of automating your investments? You can improve your returns, reduce emotional decision-making, and generally end up with better results simply by putting your investing on autopilot.
 
Jeffrey Ptak is the managing director at Morningstar. Previously, he was the chief ratings officer. 

Each week, “At the Money” discusses an important topic in money management. From portfolio construction to taxes and cutting down on fees, join Barry Ritholtz to learn the best ways to put your money to work.

See omnystudio.com/listener for privacy information.

At The Money: Automate Your Investing

Barry speaks with Jon Hilsenrath, founder of Serpa Pinto Advisory. They discuss Jon's career at the Wall Street Journal as a reporter, earning him the title of "Fed Whisperer," and the response to the Great Financial Crisis. They also discussed his belief the US is undergoing the post-industrial economic revolution. 

See omnystudio.com/listener for privacy information.

What Went Wrong in Great Financial Crisis Stimulus with Reporter Jon Hilsenrath

Land is more than just a place to build a house, commercial building or farm. Real assets can be monetized through Mineral and gas rights, solar and wind, recreation, even AI. 
 
Brandon Zick is Chief Investment Officer of Ceres Farmland Fund (now part of Wisdom Tree); they own and manage about $2 billion in agricultural land assets.
 
Each week, “At the Money” discusses an important topic in money management. From portfolio construction to taxes and cutting down on fees, join Barry Ritholtz to learn the best ways to put your money to work.

See omnystudio.com/listener for privacy information.

At The Money: Monetizing Dirt

Barry speaks with Liz Ann Sonders, chief investment strategist at Charles Schwab. Liz Ann focuses on the entire economy. She’s also the cohost of the On Investing podcast and a keynote speaker at numerous company and industry conferences. Liz Ann and Barry discuss her investment experience, working with Charles Schwab, and market cycles.

See omnystudio.com/listener for privacy information.

Market Cycles and Investment Strategy With Charles Schwab's Liz Ann Sonders

ETFs gained a reputation for providing investors with low-cost index exposure, but many of the newest funds are actively managed. Some are costly and speculative. What is an ETF investor to do?
 
Dave Nadig is President and Director of Research at ETF.com, and he shares with us how investors should navigate all of these new products. He helped design and market some of the first exchange-traded funds.
 
Each week, “At the Money” discusses an important topic in money management. From portfolio construction to taxes and cutting down on fees, join Barry Ritholtz to learn the best ways to put your money to work.

See omnystudio.com/listener for privacy information.

At The Money: How Big Can Active ETFS Get?

Make sense of the world with one essential conversation, every week. Mishal Husain, one of Britain's best interviewers, brings her signature blend of curiosity and tenacity to weekly conversations with world leaders, business titans, and cultural icons, revealing who they really are and how they see the world changing around them.

Follow the podcast wherever you listen, so you don't miss an episode.
https://link.podtrac.com/iu94w2n4

See omnystudio.com/listener for privacy information.

Introducing: The Mishal Husain Show

Barry speaks with Henry Ward, Chief Executive Officer at Carta, a technology company that provides capitalization table management and valuation software for startups. They discuss founding a business, the growth of private markets, and his lobby efforts for retail investors to access private markets.

See omnystudio.com/listener for privacy information.

Carta CEO Henry Ward on Private Credit & Private Markets

Are you underperforming our own investments? Did you know that many, maybe even most, investors do worse than the ETFs and Mutual Funds they hold do? The annual Morningstar study “Mind the Gap” has found a substantial difference between returns generated by investment funds and the actual returns investors experience.
 
Jeffrey Ptak is the managing director at Morningstar. Previously, he was the chief ratings officer.
 
Each week, “At the Money” discusses an important topic in money management. From portfolio construction to taxes and cutting down on fees, join Barry Ritholtz to learn the best ways to put your money to work.

See omnystudio.com/listener for privacy information.

At The Money: Don’t Underperform Your Own Investments!

Terri Booker’s body burns with pain. She’s one of the 100,000 Americans living with sickle cell disease – a blood disorder that can cause severe pain, organ failure, and even premature death. The genetic condition came about to protect against malaria. Dr. William Hobbs leads clinical development for sickle cell disease at Vertex, and they are investigating multiple approaches to address the unmet needs that patients face. 
 
This episode of Targeting the Toughest Diseases is sponsored by Vertex Pharmaceuticals.

See omnystudio.com/listener for privacy information.

Targeting Sickle Cell Disease (Sponsored Content)

Loe ja kuula

Muud podcastid, mis võivad sulle meeldida ...